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For years an assumption was made that C-peptide, a
byproduct of insulin biosynthesis, possessed no apprecia-
ble physiologic role. As other contributions in this volume
amply testify, the time has come to re-evaluate that notion.
C-peptide either directly through interaction with its spe-
ciﬁc cell-surface receptor or indirectly through an interac-
tion with a related membrane entity, exerts a unique effect
on several intracellular processes. We review here results of
studies attempting to elucidate such molecular effects of
C-peptide in different cell systems and tissues. Lacking a
puriﬁedC-peptidereceptor,wealsodemonstrateC-peptide
effectsondistinctelementsoftheinsulinsignaltransduction
pathways.
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INTRODUCTION AND BACKGROUND
C-peptide was ﬁrst described in 1967 as a byproduct of in-
sulinbiosynthesis(Steiner,1967).Ithadbeenacceptedforyears
thatitwasjustaninertmoleculewithnointrinsicphysiological
role.Thatviewwasfueledbyinvestigators’inabilitytodemon-
strate any apparent biological activity in assays used (such as
lowering of blood glucose concentration), by a perceived lack
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ofaspeciﬁccell-surfacepeptidereceptor,andbytheseemingly
satisfactory explanation of C-peptide’s role as a substance al-
lowing proper folding of the proinsulin molecule. That view
hasundergonetransformationoverthepastdecadeasdatahave
accumulated showing diverse biological effects after adminis-
tration of C-peptide. These results are described in detail else-
where in this volume. To summarize, in several animal models
of diabetes and in patients with autoimmune insulin-deﬁcient
(type 1) diabetes mellitus, C-peptide replacement seems to en-
hance skin and skeletal muscle blood ﬂow, to improve renal
function, to ameliorate sensory nerve dysfunction, to acceler-
ate sural and peroneal nerve conduction velocity, to improve
autonomic nerve function, to augment glucose utilization, and
to ameliorate impaired deformability of erythrocytes.
Although the decade of 1990s showed conclusively that
C-peptide has biological effects, it remains for the 2000s to
settle the question of speciﬁc molecular mechanism(s) respon-
sible for these observations.
It has been accepted for several decades that for any peptide
hormone to exert speciﬁc cellular effects, a speciﬁc receptor
should be identiﬁable at the cell surface. Typically, the hor-
mone binds in a saturable, reversible manner and activates spe-
ciﬁc intracellular events. Identifying such a speciﬁc receptor
for proinsulin C-peptide has proven elusive. As a result, many
of the previously shown effects of C-peptide were instead ex-
plained by nonchiral membrane interactions (Ido et al., 1997).
It was not until 1999 when the ﬁrst credible report identiﬁed
speciﬁc C-peptide binding to cell membranes in cultured renal
tubularcells,andsaphenousveinendothelialcells(Rigleretal.,
1999). The technique used in that report, ﬂuorescence correla-
tionspectroscopy,isapparentlysensitiveenoughtodemonstrate
the presence of speciﬁc ligand-receptor interactions where the
traditional radioligand methods had previously failed.
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The question that needs to be settled is whether the unequiv-
ocally observed biological effects of C-peptide are mediated
by the peptide’s direct and speciﬁc interaction with a cognate
receptor or indirectly through and interaction with a receptor
for different ligand(s).
WhathavebeentheintracellulareffectsofC-peptidethatcall
for investigations of their molecular underpinnings? C-peptide,
for example, stimulates glucose transport in human skeletal
muscle(Zierathetal.,1996)inadose-dependentfashion.InL-6
myoblasts, C-peptide increases glycogen synthesis and amino
acid uptake (Grunberger et al., 2001). Early on, C-peptide was
found to enhance Na+,K+-ATPase activity in rat sciatic nerve,
granulation tissue, red cells, pancreatic islets, renal cells, and
other tissues. Further, C-peptide activates endothelial nitric ox-
ide synthase, resulting in release of nitric oxide from bovine
aortic endothelial cells (Wahren et al., 2000). These 2 mech-
anisms have been accepted as the underlying principles of
C-peptide’sbiologicaleffects.However,movingfromthephys-
iologicalobservationstotheintracellularenzymologystillbegs
the questions as to what is the proximal speciﬁc molecular
mechanism which C-peptide triggers upon encountering the
cell membrane.
NATURE OF THE C-PEPTIDE RECEPTOR
Rigler et al. (1999), in their above-referenced paper, which
identiﬁedC-peptidebindingtohumancellmembranes,reported
an inhibitory effect of pertussis toxin on the speciﬁc interaction
of C-peptide with the cell surface. This ﬁnding led to their con-
clusion that the C-peptide–stimulatedNa+,K+-ATPase activity
involvedGproteins.TheypostulatedthataGproteininteracting
with a ligand-activated receptor might constitute an allosteric
system. Pertussis toxin might then interfere with interaction
between the G protein and the loop regions of the membrane-
spanning receptor. These results were consistent with previous
reports showing that pertussis toxin and protein phosphatase
2B (calcineurin) inhibitor abolished Na+,K+-ATPase activity
in rat renal tubular segments (Ohtomo et al., 1996). A possible
scenario of C-peptide signaling would then include activation
of a speciﬁc pertussis toxin-sensitive G protein–coupled re-
ceptor and activation of a calcium-dependent intracellular
signaling.
C-PEPTIDE SIGNAL TRANSDUCTION
IN HUMAN SKELETAL MUSCLE
The initial attempt to answer the question was published
by Zierath et al. (1996). They studied the molecular basis
of C-peptide–stimulated glucose transport in human skeletal
muscle. Isolated muscle tissue was obtained by open biopsy
from the vastus lateralis portion of the quadriceps muscle
from healthy and type 1 diabetic subjects. They reported that
both insulin (6 nmol/L) and C-peptide (2.5 nmol/L) increased
3-O-methylglucose transport about 2-fold. Interestingly, coin-
cubation of the muscle strips with both insulin and C-peptide at
the above physiological concentrations resulted in the same de-
greeofstimulationaswitheitherhormonealone.Inviewofthe
nonadditivity of the peptide affects, the authors concluded that
C-peptide likely activates glucose transport in human skeletal
muscle via an insulin-mediated system. Thus, they set up to
investigate whether C-peptide interacted with the insulin re-
ceptor and the proximal parts of the insulin-signaling pathway.
They could not demonstrate speciﬁc binding of radiolabeled
C-peptide to crude membranes prepared from the muscle,
nor tyrosine kinase activity of partially puriﬁed insulin recep-
tors from that tissue. Differences in C-peptide– and insulin-
mediated signaling were inferred from the results of stud-
ies using isoproterenol, a β-adrenergic agonist. Isoproterenol
inhibited insulin-stimulated but not the C-peptide–stimulated
glucose transport. On the other hand, the c-AMP analog,
Bt2cAMP, abolished both insulin- and C-peptide–stimulated
effects. The authors’ results thus left the molecular mechanism
of the C-peptide’s insulinomimetic effect unanswered. They
concluded that a possible explanation for the nonadditivity of
C-peptide and insulin effects, in the absence of C-peptide–
activated insulin receptor binding and tyrosine kinase activity,
might be signaling pathways shared by the 2 hormones distal
to the tyrosine kinase activation.
C-PEPTIDE SIGNALING IN SWISS 3T3
FIBROBLASTS AND 3T3-F442A CELLS
ThehypothesiswaspursuedbyKitamuraetal.(2001).They
showed that human and rat (1 and 2) C-peptide stimulated
phosphorylation of mitogen-activated protein kinase (MAPK)
in Swiss 3T3 ﬁbroblasts and 3T3-F442A cells. Interestingly,
they failed to see the same effect in other cells (3T3-L1 ﬁbrob-
lasts, HepG2 hepatoma, C6 glioma, L6E9muscle, NG108.15
neuroblastoma, and GH4C1 somatomamotrophic cells), em-
phasizing the importance of cell speciﬁcity and the danger of
simple extrapolation of data from one system to another. In
the responsive cells, C-peptide increased MAPK phosphory-
lation at concentrations between 1 pM and 1 nM (half max-
imal dose was 0.25 nM for p44 MAPK and 0.28 nM for
p42 MAPK). Higher concentrations of C-peptide were not ef-
fective and there was no increase in total MAPK concentra-
tions induced by any dose of C-peptide. Insulin was used at
100timeshigherconcentration(100nM)andhad2-foldhigher
maximum effect on MAPK phosphorylation than C-peptide.
The investigators, unfortunately, did not assess simultaneous
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of the hormones’ actions. In more detailed pursuit of mecha-
nismofC-peptideeffect,C-peptidewasfoundtophosphorylate
mitogen-activated protein kinase kinase (MAPKK) (MEK), an
enzyme that phosphorylates and activates MAPK. PD98059, a
MEK inhibitor, abolished that stimulatory action of C-peptide.
Pertussis toxin preincubation of cells led to inhibition of
C-peptide–stimulated MAPK phosphorylation. The authors
concluded that C-peptide activates MAPK through a Gi/G0-
linked receptor. In investigating additional potential signal-
ing pathways activated by C-peptide, Kitamura et al. (2001)
assessed a possible effect of wortmannin, a phosphoinositol
3-kinase (PI3K) inhibitor on C-peptide–stimulated MAPK
phosphorylation. Wortmannin inhibited the C-peptide effect.
Similarly, GF 109203X, a protein kinase C inhibitor, abol-
ished the C-peptide–induced MAPK phosphorylation. Pre-
treatment of cells with phorbolmyristate acetate (PMA)
down-regulated protein kinase C activity. It also inhibited the
abilityofC-peptidetostimulateMAPKphosphorylationinsuch
cells. From these experiments, C-peptide would thus seem to
mediate its cellular effects via PI3K-dependent and protein ki-
nase C–dependent pathways.
C-PEPTIDE SIGNALING IN LEII MOUSE LUNG
ENDOTHELIAL CELLS
The same authors (Kitamura et al., 2002) also examined
effects of C-peptide in LEII mouse lung capillary endothelial
cells. They demonstrated that human C-peptide (at 10 nM) in-
duced an increase of ERK 1/2 phosphorylation (just as insulin
did,at100nM).C-peptidealsoledtosite-speciﬁcphosphoryla-
tion of p38 MAPK (Thr-183/Tyr-185), whereas insulin did not.
C-peptide(1nM)-inducedphosphorylationofERK1/2andp38
MAPK led to enhanced kinase activities of these enzymes (ap-
proximately 3-fold). This effect of human C-peptide was repli-
cated using rat C-peptides 1 and 2; neither retrosequenced nor
all D-amino acid human C-peptide induced phosphorylation of
thesekinases.Topursuethesequenceofeventsinducedbyincu-
bationofLEIIcellswithC-peptide,theauthorsalsoshowedthat
phosphorylationofthecAMPresponseelement-bindingprotein
(CREB), activating transcription factor (ATF)1, and ATF2 (but
not that of c-Jun, a substrate of c-Jun N-terminal kinase [JNK])
were increased. The C-peptide–induced phosphorylation was
conﬁrmed to promote the binding of CREB/ATF family pro-
teinstoDNA.InordertodeterminetheinvolvementofERK1/2
and p38 MAPK in the observed C-peptide effects on phos-
phorylation of CREB/ATF, the authors used several speciﬁc
inhibitors. SB203580, a p38 MAPK inhibitor, abolished the
C-peptide–induced phosphorylation of CREB/ATF and acti-
vation of p38 MAPK. PD98059, a MEK inhibitor, in con-
trast, had no such effect. Because there are intermediate
steps between activation of p38 MAPK and phosphoryla-
tion of CREB/ATF, Kitamura et al. (2002) assessed activa-
tion of mitogen- and stress-activated protein kinase (MSK1),
MAPKAP-K2, and ribosomal S6 kinase (RSK), all CREB
kinases. C-peptide increased phosphorylation of MAPKAP-
K2 and RSK. In turn, SB203580 (but not PD98059) inhib-
ited this effect. Thus, it appears that C-peptide enhanced
p38 MAPK followed by MAPKAP-K2 to increase inter-
actions between CREB/ATF1 and DNA. The effects of
C-peptide in the LEII cells were not identical to those of in-
sulin. Insulin induced phosphorylation of ERK 1/2 but not that
of p38 MAPK.
C-PEPTIDE SIGNALING IN RAT MEDULLARY
ASCENDING LIMB OF HENLE’S LOOP
Tsimaratos et al. (2003) studied the molecular mecha-
nismsunderlyingC-peptide–stimulatedNa+,K+-ATPaseactiv-
ity in isolated rat medullary thick ascending limb of Henle’s
loop. C-peptide–mediated increases in the enzyme activity was
observed at physiological concentrations between 1 and
100 nM, with maximal effect at 100 nM at 37◦C within 5 min-
utes of incubation of the medullary segments with C-peptide.
The ATPase stimulation by C-peptide reached a plateau after
10 minutes. The scrambled sequence of C-peptide did not al-
ter Na+,K+-ATPase activity. Apparently, the C-peptide effect
was caused by increased turnover of the enzyme in this cell
system. The stimulation of the ATPase activity was associated
with enhanced phosphorylation of its α-subunit. C-peptide, at
100 nM, stimulated the appearance of the α-isoform of protein
kinaseC(PKC)inthemembranefraction.Theamountsofother
PKC fractions assessed in these studies were not affected by
C-peptide preincubation of the segments. GF109203X, a spe-
ciﬁc PKC inhibitor, abolished the stimulatory effect of 100 nM
C-peptide. The authors, therefore, concluded that the observed
stimulation of Na+,K+-ATPase catalytic α-subunit activity is
PKC-α dependent.
MOLECULAR BASIS FOR THE
INSULINOMIMETIC EFFECTS OF C-PEPTIDE
IN RAT SKELETAL MUSCLE CELLS
Grunberger et al. (2001) showed that synthetic rat C-peptide
stimulates several insulin-like cellular effects in a rat skeletal
muscle cell system. To elucidate the molecular mechanisms(s)
underpinning such insulinomimetic actions as glycogen syn-
thesis and amino acid uptake, they investigated the effects of
C-peptide on several elements of the insulin signaling pathway.
Physiologic effects of insulin are initiated by insulin bind-
ing to the extracellular domain of the insulin receptor (IR).
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followed by phosphorylation of intracellular substrates, prop-
agating receptor signals throughout the cell. These include the
Ras/MAPK cascade and the PI3K/Akt (protein kinase B, PKB)
system, which are thought to play key roles in the mitogenic
and metabolic arms of insulin signaling, respectively (Holman
andKasuga,1997;Virkam¨ akietal.,1999).C-peptideenhances
insulin-stimulated IR autophosphorylation and TKA in vitro
(Simaetal.,1998).Basedonthoseobservations,itwashypoth-
esized that C-peptide could affect other downstream elements
of insulin signal transduction pathways.
Preincubation with rat-II C-peptide led to a 2.5-fold in-
crease in glycogen synthesis in L6 rat myoblasts. The dose-
dependent effect of C-peptide showed a bell-shaped response
(Figure 1A). Maximum effect was observed between 1 and
3nMofC-peptide.Interestingly,itrequired10nMofinsulinto
FIGURE 1
Stimulation of glycogen synthesis by C-peptide in L6 myoblasts. (A) L6 cells were serum-starved for 16 hours and then
incubated with insulin, C-peptide, or scrambled C-peptide sequence for 1 hour. (B) L6 cells were serum-starved for 16 hours and
then incubated with a combination of insulin and C-peptide for 1 hour. Results seen with 10 nmol/L insulin are shown for
comparison. Glycogen synthesis was assessed by measuring D-[14C]glucose incorporation into glycogen. Results are plotted as
mean ± SEM of 10 separate experiments (each done in quadruplicate) and normalized with respect to control (=100%).
Reproduced from Grunberger et al., 2001, by permission of Diabetologia. ∗∗∗P <. 001, ∗∗P <. 01, ∗P <. 05 versus control (A);
and †P <. 05 versus every sample, #P <. 05 versus insulin (10 nmol/L) (B).
achievethe2-foldstimulationseenwith0.3nMofC-peptide.A
scrambled C-peptide sequence (random arrangement of the 31
aminoacidsofC-peptide),servingasacontrol,didnotincrease
glycogen synthesis above basal level. Human C-peptide in-
creased glycogen synthesis to the same degree as the homolo-
gous (rat) C-peptide. Combinations of submaximally effective
insulin (10 nM) and submaximal concentrations of C-peptide
(0.1or0.3nM)increasedglycogensynthesisoverthatachieved
with either ligand alone (Figure 1B). Combinations of maxi-
mally effective concentrations of insulin and C-peptide, how-
ever, were not additive.
C-peptide (1 to 10 nM) stimulated amino acid uptake more
than 2-fold in L6 myoblasts, an effect similar to that of 10 nM
of insulin (Figure 2A). Statistically signiﬁcant stimulation
was documented between 0.3 nM and 10 nM of C-peptide.THE C-PEPTIDE SIGNALING 29
FIGURE 2
Stimulation of [14C]aminoisobutyric acid uptake in L6 myoblasts. (A) L6 cells were serum-starved for 16 hours and then
incubated with insulin, C-peptide, or a scrambled C-peptide sequence (SC-peptide) for 1 hour. (B) L6 cells were serum-starved
and then incubated with a combination of insulin and C-peptide for 1 hour. Results obtained with 10 nmol/L insulin are shown for
comparison. Amino acid uptake was measured by [14C]methylaminoisobutyric acid incorporation. Results are presented as mean
± SEM of 3 separate experiments. Reproduced from Grunberger et al., 2001, by permission of Diabetologia. ∗∗∗P <. 001,
∗∗P <. 01, ∗P <. 05 versus control (A), †P <. 05 versus every sample, #P <. 05 versus insulin, 10 nmol/L.
Incubation of the cells with scrambled C-peptide did not in-
crease the aminoisobutyric acid uptake over baseline. Addition
ofC-peptide(0.1to1nM)tothesubmaximallyeffectiveinsulin
concentration (10 nM) signiﬁcantly increased the amino acid
uptake achieved with insulin alone (Figure 2B).
Based on the insulinomimetic effect of C-peptide on glyco-
gen synthesis, the molecular basis for this observation was
pursued. Insulin exerts its stimulatory effect on glycogen syn-
thasebybothactivatingproteinphosphatase1andbyinhibiting
glycogensynthasekinase(GSK3),whichisinactivatedbyphos-
phorylation (Halse et al., 1999). Preincubation of the cells with
physiological concentrations of C-peptide (0.3 to 3 nM) led to
increasedGSK3phosphorylation(7.5-and5-fold,respectively)
(Figure3).Thecombinationsof10nMinsulinwitheither0.1or
0.3 nM C-peptide showed statistically signiﬁcant increases in
GSK3phosphorylationovertheeffectofeitherhormonealone.
C-peptidethusstimulatesglycogensynthesis,atleastpartly,by
inhibition of GSK3. Clearly, modulation of GSK3 is not the
only mechanism by which glycogen synthesis is stimulated.
Insulin activates phosphorylation of Akt in L6 cells. Con-
trary to expectations raised by the insulinomimetic effects
of C-peptide on glycogen synthesis, amino acid uptake, and
GSK3 phosphorylation, C-peptide (at concentrations of up to
30 nM) did not stimulate phosphorylation of Akt whether it
was assessed by immunoprecipitating or by immunoblotting
with an anti–phospho-Akt antibody (Thr-308). Further, in a
separate study, intact L6 myotubes were labeled with 32P-
orthophosphoric acid for 6 hours, and stimulated with insulin,
withC-peptide(0.3,3nM),withscrambledC-peptide(0.3nM),
or a combination of insulin and C-peptide. Cell lysates were
immunoprecipitated with anti-Akt 1 antibody. Insulin (10 nM)
stimulated phosphorylation of Akt 3.1-fold, but C-peptide did
not. These data indicate that the observed insulinomimetic bi-
ological effects of C-peptide (Figures 1 and 2) likely involve
divergent signaling pathways proximal to Akt activation.
Incubation of L6 myoblasts with C-peptide, with concentra-
tions as low as 0.3 nM, also led to stimulation of Rsk phos-
phorylation (2.6-fold). Activation of Rsk was also ascertained
by assessing its enzyme activity, using the p70S6 Rsk sub-
strate (RRRLSSLRA). C-peptide, at 0.3 and 3 nM, activated
Rsk as did insulin (10 and 100 nM) in L6 myoblasts. Combina-
tion of submaximally effective insulin concentration (10 nM)30 G. GRUNBERGER AND A. A. F. SIMA
FIGURE 3
Stimulation of GSK-3 phosphorylation by C-peptide.
Serum-starved conﬂuent L6 myoblasts were incubated with
insulin, C-peptide, or scrambled C-peptide sequence for
10 minutes. Cell lysates were separated by 7.5% SDS-PAGE,
transferred to nitrocellulose membrane, and immunoblotted
with anti–phospho-GSK3 antibody. Data from 4 separate
experiments are plotted as mean ± SEM for each condition
normalized for control (=100%). Reproduced from
Grunberger et al., 2001, by permission of Diabetologia.
∗∗∗P <. 001, ∗∗P <. 01, ∗P <. 05 versus control; #P <. 05
versus insulin (10 nmol/L).
C-peptide (0.1 and 3 nM) increased the Rsk activity over that
achieved with 10 nM insulin alone.
Biological actions of insulin in skeletal muscle are medi-
ated by a complex interplay of multiple signaling cascades
(Virkam¨ aki et al., 1999). One of these insulin-activated sig-
naling pathways involves stimulation of phosphorylation and
activation of MAPK or extracellular regulated kinase (ERK).
Both insulin and C-peptide (between 0.3 and 10 nM) increased
phosphorylationofMAPKinL6myoblastsandindifferentiated
3T3-L1adipocytes(Figure4).Incubationswitheitherinsulinor
C-peptide did not signiﬁcantly alter ERK protein expression in
those cells. Incubation with C-peptide led to a 1.5- to 4-fold in-
creaseinL6myoblastsand3T3-L1adipocyteswhentheresults
were expressed as phosphorylated MAPK/ERK2 ratio.
To assess the potential role of PI3Ks in C-peptide stimula-
tion of glycogen synthesis in L6 myoblasts, glycogen synthesis
was assessed in the presence of a PI3K inhibitor. Wortmannin
(at 100 nM) completely abolished the C-peptide–, insulin- as
wellasthecombinationofC-peptide/insulin–stimulatedglyco-
gen synthesis (Figure 5). These data indicate involvement of
wortmannin-sensitiveclass1Aor3PI3Ks(Frumanetal.,1998)
FIGURE 4
Activation of MAPK by C-peptide in L6 myoblasts and
3T3-L1 cells. Cells were incubated with insulin, C-peptide,
and a combination of insulin and C-peptide for 10 minutes.
Cell lysates were separated on Ready gel, transferred to
nitrocellulose membrane, and immunoblotted with
anti–phospho-MAPK antibody. Quantitation of data
(4 separate experiments) is shown as mean ± SEM for each
condition normalized for control (=100%). Reproduced from
Grunberger et al., 2001, by permission of Diabetologia.
∗∗∗P   .001, ∗∗P <. 01, ∗P <. 05 versus control.
in the C-peptide–stimulated glycogen synthesis. In an insulin-
responsive, differentiated 3T3-L1 adipocyte system used as a
control system, insulin stimulated the PI3K activity associated
with tyrosine-phosphorylated proteins. C-peptide (100 nM) in-
creased (∼2-fold) PI3K activity in these anti-phosphotyrosine
immunoprecipitates. C-peptide at concentrations of 1, 10, and
100 nM increased PI3K activity in a dose-dependent manner.
When the assays were done in the presence of wortmannin,
PI3K activity was completely abolished. The combination of
submaximal concentrations of C-peptide (0.5 nM) with sub-
maximal insulin (1 and 10 nM) increased PI3K activity above
that seen with insulin (10 nM) alone. C-peptide increased the
activationofPI3Kbyabout60%.Ithastobenoted,though,that
thisassayonlyassessestheactivityofthatsmallportionofPI3K
that associates with anti-phosphotyrosine immunoprecipitates
(about1%to4%ofthetotalPI3Kactivity).Unlikewortmannin,
which inhibited both insulin and C-peptide glycogen synthesis,
pertussis toxin had no such effect in L6 myoblasts (Figure 5).
To study the upstream mediator(s) of C-peptide–induced
PI3Kactivation.L6myoblastsweretreatedwithC-peptide(0.3
and3nM)orinsulin(10and100nM),correspondingtothesub-
maximal and maximal effective doses, respectively, as deter-
mined in the glycogen synthesis and amino acid uptake experi-
ments (Figures 1 and 2). Cell lysates were immunoprecipitated
with anti–insulin receptor substrate-1 (IRS-1) antibody and theTHE C-PEPTIDE SIGNALING 31
FIGURE 5
C-peptide–stimulated glycogen synthesis in L6 myoblasts is wortmannin sensitive but pertussis toxin independent. Monolayers
of conﬂuent L6 myoblasts were serum-starved for 16 hours, pretreated with either wortmannin (100 nmol/L) for 30 minutes or
with pertussis toxin (1 µg/mL) for 4 hours and then incubated with insulin (100 nmol/L), with C-peptide (0.3 nmol/L), or with
insulin and C-peptide combinations for 1 hour. Glycogen synthesis was assessed by measuring D-[14C]glucose incorporation into
glycogen. Results are plotted as mean ± SEM of 4 separate experiments (each done in quadruplicate) and normalized with
respect to control (=100%). Reproduced from Grunberger et al., 2001, by permission of Diabetologia. ∗∗∗P <. 001, ∗∗P <. 01,
∗P <. 05 versus control.
resultingimmunocomplexesweresubjectedtoimmunoblotting
with anti-phosphotyrosine antibody. C-peptide at both 0.3 and
3 nM also signiﬁcantly increased tyrosine phosphorylation of
IRS-1. These data suggest that activation of IRS-1 is involved
in C-peptide signaling pathway.
Binding to its receptor and activation of the insulin receptor
tyrosine kinase activity (IR-TKA) initiate the bioeffects of
insulin. Because C-peptide increased glycogen synthesis and
amino acid uptake in insulin-responsive cells, the ability of
C-peptide to stimulate TKA in solubilized L6 receptors was
tested. C-peptide by itself increased TKA of the extracts in
a dose-dependent manner. The bell-shaped concentration re-
sponse,withmaximumeffectsoccurringbetween1and10nM,
is depicted in Figure 6A. The statistically signiﬁcant increase
inTKAcausedbyC-peptidewascomparabletothatstimulated
by 10 nM insulin. Concentrations of C-peptide leading to the
maximumTKAwerethusintherangeseenphysiologicallyand
in the glycogen synthesis and amino acid uptake experiments
(Figures 1 and 2). Comparing with submaximally effective
insulin (10 nM) concentration, the combination of insulin
and C-peptide increased TKA of the L6 myoblast membrane
extracts over that of either ligand alone (Figure 6B). These
results suggest that the insulinomimetic effects of C-peptide
in L6 cells could be initiated by activation of TKA. To
determine whether IR contributes the TKA stimulated in these
experiments by C-peptide, immunoprecipitated IRs (from the
wheat germ agglutinin (WGA)-puriﬁed membrane preparation
using an antibody against IR-β-subunit) were used in an in
vitro kinase assay. C-peptide (0.3 and 3 nM) exerted a 2-fold
stimulation of IR TKA. Combination of submaximal insulin
(10 nM) and C-peptide (0.3 nM) concentrations increased IR
TKA to the same degree as either ligand alone. C-peptide (0.3
and 3 nM) increased IR phosphorylation on tyrosine residues
3- to 4-fold in L6 myoblasts. These data suggest that the32 G. GRUNBERGER AND A. A. F. SIMA
FIGURE 6
C-peptide activates tyrosine kinase in L6 myoblasts. (A) Receptors partially puriﬁed from L6 plasma membranes were incubated
with insulin, C-peptide, or scrambled C-peptide. (B) Receptors were incubated with combinations of insulin and C-peptide.
Tyrosine kinase activity of the receptors was assayed by phosphorylation of the synthetic substrate poly (Glu4Tyr1) in the presence
of [γ-32P]ATP. Results are shown as mean ± SEM of 3 separate experiments (each done in quadruplicate) and normalized with
respect to control (=100%). Reproduced from Grunberger et al., 2001, by permission of Diabetologia. ∗∗∗P <. 001, ∗∗P <. 01,
∗P <. 05 versus control; †P <. 05 versus every sample, #P <. 05, ##P <. 01 versus insulin (10 nmol/L).
C-peptide–induced TKA could be at least partly contributed
by IR present in the L6 membrane preparations.
Thus, C-peptide, at physiological concentrations, mim-
ics such insulin effects as glycogen synthesis and amino
acid uptake in rat muscle cells. C-peptide also stimulates
3-O-methylglucose transport in human skeletal muscle strips
(Zierathetal.,1991,1996).C-peptide,atphysiologicalconcen-
trations(generallybetween0.3and3nM),mimicsqualitatively
the effects of insulin. An exception occurred in the case of Akt
(PKB),whereC-peptidehadnoeffect.Aktisbelievedtobenec-
essary for the insulin-induced activation of glycogen synthesis
in L6 myotubes (Takata et al., 1999). Stimulation of glycogen
synthase by insulin is mediated by dephosphorylation through
activation of glycogen-associated protein phosphatase (PP1G)
and inhibition of GSK3, which, in turn, is inhibited by phos-
phorylation. There are at least 3 plausible kinases that could
phosphorylateGSK3orPP1G:p70S6kinase,p90Rsk,andAkt.
C-peptidestimulatesglycogensynthesiswithoutactivatingAkt.
Whetherthisresponseismediatedbyap70S6k-and/orp90Rsk-
dependent (Shepherd et al., 1995) and Akt-independent path-
way(s) is being investigated. Because of the presence of addi-
tional mechanisms (e.g., stimulation of PPG1) for regulation
of glycogen synthesis, only qualitative comparisons should be
drawn at this time between our data on C-peptide’s effect on
glycogen synthesis and GSK3 phosphorylation.
Given the reported cellular and tissue effects of C-peptide
anditsbeneﬁcialeffectsintype1diabeticpatientsandinanimal
models(Wuetal.,1996;Sjokvistetal.,1998;Simaetal.,1999;
Sima,2003a,2003b;Johanssonetal.,1992;Ekbergetal.,2003),
the question still remains as to the molecular underpinnings
for these observations. There are at least 4 distinct possibilities
for explaining our data (Figure 7). First, C-peptide effects
could result from direct binding to and activation of a speciﬁc
C-peptidereceptor.Aputativereceptor,demonstratedbyRigler
et al. (1999), is proposed to be a surface entity coupled to its
signal transduction pathway(s) via a G protein. The latter hy-
pothesisisbasedonthedemonstrationofbluntingtheC-peptide
effects by pertussis toxin. The data in L6 myoblasts do notTHE C-PEPTIDE SIGNALING 33
FIGURE 7
Possible mechanisms of C-peptide effects.
indicate any effect of pertussis toxin on C-peptide–stimulated
glycogen synthesis, however. The second possibility is that
C-peptideactivatestheIR.ThelackofC-peptidestimulationof
glycogen synthesis in the parental rat 1 ﬁbroblasts (which con-
tain few IR) but robust effects in HIRcB cells (overexpressing
humanIR)supportaroleofIRinmediatingtheC-peptideeffect.
GiventhestructuraldifferencesbetweeninsulinandC-peptide,
the interaction with IR would need to occur with an α-subunit
domain distinct from that responsible for insulin binding to
IR. Alternatively, a plasma membrane perturbation caused by
C-peptide could lead indirectly to a conformational change
of the IR, leading to activation of its β-subunit, i.e., its
autophosphorylation and activation of tyrosine kinase. The fact
that only submaximal concentrations of both C-peptide and
insulin are additive suggests sharing of at least some elements
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Jensen and Messina (1999) showed, in smooth muscle arte-
rioles, that the effect of C-peptide on arteriolar dilation was
potentiated in the presence of low insulin concentrations alone.
They concluded that the C-peptide interaction with insulin
is biologically important and concentration dependent. This
interaction might be missing in patients treated solely with in-
sulin replacement. The third possibility is a combination of the
two above: interaction of C-peptide with its cognate membrane
receptor and with a speciﬁc domain of the IR. A fourth option
is an interaction of C-peptide with another cell surface receptor
such as the insulin-like growth factor (IGF)-1 receptor. IGF-1
and C-peptide share structural domains, which could form the
basis for cross-talk between their signaling pathways. We have
already shown that C-peptide replacement normalizes both
IGF and IGF-1 receptor expression (Li et al., 2000; Sima et al.,
2001).
TherespectiveinsulinandC-peptideconcentration-response
curves deserve mention. Typically, 10 nM insulin is necessary
to document statistically signiﬁcant responses in in vitro sys-
tems. Higher insulin concentrations increase the effect, with
100 to 1000 nM resulting in the maximal stimulation of a re-
sponsetestedinthevariousassays.Incontrast,considerablyless
C-peptide, on a molar basis, is sufﬁcient to elicit insulin-like
responses, even though in absolute terms, these are less robust
thanthoseseenwithinsulinalone.PeaksofC-peptideresponses
arereachedat∼0.3to3nM.Interestingly,halfsaturationofthe
putativeC-peptidereceptoroccursat0.3nMandfullsaturation
at0.9nMofthepeptide(Rigleretal.,1999),i.e.,concentrations
foundfullyeffectiveintheL6cellsystem.Incontrasttoinsulin,
higher doses of C-peptide (>10 nM) result in blunting of the
stimulatory responses. Any extrapolation of these observations
intomammalianphysiologyis,ofcourse,premature.Onewon-
ders, however, whether the additivity of low C-peptide and low
insulin concentrations could be advantageous for fuel storage.
Conversely, in the postprandial situation, in the presence of ex-
uberantinsulinrelease,theconcomitanthigherC-peptidelevels
would serve to blunt insulin’s peripheral effects.
C-PEPTIDE EFFECT ON PROTEIN
TYROSINE PHOSPHATASE IN L6 RAT
SKELETAL MYOBLASTS
Based on the ﬁnding that C-peptide mimicked at least partly
the molecular details of insulin signal transduction, Li et al.
(2001)testedthehypothesisthatC-peptideaffectedtheactivity
of protein tyrosine phosphatase (PTP). C-peptide indeed inhib-
itedPTPactivityinratskeletalmusclecellsinadose-dependent
manner. Maximum inhibition appeared at 3 nM of C-peptide,
the same concentration as the maximum stimulatory effect of
C-peptide on glycogen synthesis. Scrambled C-peptide se-
quence had no effect on PTP activity. Autophosphorylation of
the IR and activation of IRS-1 were enhanced by C-peptide.
These ﬁndings thus provide evidence for possible mechanisms
underlying the insulinomimetic effects of C-peptide. C-peptide
could be envisioned to interact with the IR or could cross-talk
withtheIRsignalingpathwayataproximalpoint.Ofcourse,an-
other possibility would include C-peptide ﬁrst interacting with
itsspeciﬁcGprotein–coupledreceptor,leadingtoaconsequent
cross-talk with the IR signal transduction pathway.
EFFECTS OF C-PEPTIDE
ON NEURONAL APOPTOSIS
Inanotherattempttoestablishthemolecularmechanismsre-
sponsibleforthesalutaryC-peptideeffectsondiabeticneuropa-
thy,thegroupofSimastudiedhumanneuroblastomaSH-SY5Y
cells (Li et al., 2003; Sima, 2003a). They demonstrated that
C-peptide stimulated cell proliferation and neurite outgrowth.
Cell numbers increased with duration of treatment, reaching
maximum at 4 days. Cell number increase was dose dependent,
withmaximumeffectobservedat3nMofC-peptide.Scrambled
C-peptidedidnotaffectcellproliferation.Asexpected,insulin,
at4nM,wasalsoastimulatorofcellproliferation.Signiﬁcantly,
insulin’s effect was enhanced by the addition of physiological
doses (1 to 3 nM) of C-peptide. IGF-1 (at 1 nM) also increased
cell numbers and its effect was enhanced by 1 to 10 nM of
C-peptide. For neurite outgrowth, results were mostly anal-
ogous to the cell proliferation part of the experiments. The
addition of C-peptide (3 to 10 nM) increased the neurite
outgrowth over and above that seen with either insulin or
C-peptide alone. Interestingly, addition of C-peptide did not
enhance the effect of IGF-1 (1 nM) alone. Scrambled-sequence
C-peptide again had no effect on the neurite outgrowth. These
cellular effects of C-peptide were likely the result of increased
antiapoptosis. The authors examined glucose-induced apop-
tosis (at 5 to 200 mM range). The percentage of apoptotic
cells grew with increased glucose concentrations. Effects
of C-peptide on glucose-induced apoptosis were tested at
100 mM glucose concentration. C-peptide by itself (at 3 nM),
in contrast to insulin (at 4 nM), had no protective effect on
glucose- or mannitol-induced apoptosis. The combination of
insulin and C-peptide led to enhancement of the antiapoptotic
effects of either insulin or C-peptide alone. Results were the
same when apoptosis was examined by nuclear condensation.
Combination of C-peptide and insulin resulted in a more
dramatic protection against apoptosis than the effect of insulin
alone. Neither insulin nor C-peptide affected expression of
Bcl2 or nuclear factor (NF)-κB. The combination of C-peptide
and insulin, however, signiﬁcantly increased the expression of
both Bcl2 and NF-κB. Likewise, the combination of C-peptideTHE C-PEPTIDE SIGNALING 35
and insulin enhanced translocation of NF-κB to the nuclei over
the effect of insulin alone.
Interestingly, C-peptide, in the concentration of 3 nM and in
presence of 4 nM insulin, signiﬁcantly enhanced autophospho-
rylation of the IR. Further, the combination of C-peptide and
insulin in this cell system increased phosphorylation of p38
MAPK, stimulated PI3K activity in antiphosphotyrosine im-
munoprecipitates, increased the expression and translocation
of NF-κB, enhanced expression of Bcl2, and reduced phospho-
rylation of JNK. All of these effects were signiﬁcantly higher
than those seen in presence of insulin alone. C-peptide by itself
had no effects on any of these signaling elements. Finally, no
enhancement of tyrosine phosphorylation of a related receptor,
that for IGF-1, was detected in presence of the combination of
C-peptideandinsulin.Theauthorsconcludedthattheantiapop-
totic effect of C-peptide enhances that of insulin, but through a
different mechanism from that induced by IGF-1. Given their
data, C-peptide could possibly lead to antiapoptotic action by
increased phosphorylation of several cellular proteins, includ-
ing those involved in the insulin signaling pathways.
Therefore, these effects of C-peptide in human neuroblas-
toma cells, occurring in the presence of submaximal concen-
trations of insulin, are similar to those reported by Jensen and
Messina (1999) showing that the concentration-dependent ar-
teriolar dilatation by C-peptide occurs only in the presence of
insulin.
In summary, it is clear that C-peptide alone or in combina-
tionwithlowinsulinconcentrationsmimicsseveralofinsulin’s
biological effects. In insulin-sensitive L6 myoblasts, differen-
tiated myocytes, adipocytes, and neuroblastoma cells, the sig-
nal transduction pathways activated by C-peptide are similar
to those used by insulin. The receptor through which the C-
peptideactivitiesaretransmitted,however,remainselusive.The
elucidation of its nature and cloning and details of the interac-
tionbetweentheinsulinandC-peptidesignalingpathwayspose
important challenges for the immediate future.
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